Pfizer's Latest Immunotherapy Deal Could Be Great News for This Tiny Company – Madison.com

Pfizer’s Latest Immunotherapy Deal Could Be Great News for This Tiny Company
Madison.com
Last week, Pfizer (NYSE: PFE) agreed to a deal with privately held biopharma company OncoImmune. It could be worth up to $250 million in up-front and milestone payments if the monoclonal antibody at the center of the licensing agreement succeeds.

and more »

Read More…

Share This: